scholarly journals Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

2016 ◽  
Vol 17 (1) ◽  
pp. 61-66
Author(s):  
Katarina Vesic ◽  
Slavica Djukic Dejanovic ◽  
Milica Borovcanin ◽  
Janko Samardzic ◽  
Gordana Toncev
Keyword(s):  
Multiple Sclerosis ◽  
Cannabinoid Receptor ◽  
Therapeutic Potential ◽  
Positive Impact ◽  
Moderate Intensity ◽  
Symptom Improvement ◽  
Clinical Environment ◽  
Cannabinoid Receptor 2 ◽  
Multiple Sclerosis Patients ◽  
Based Medicine

Abstract The therapeutic potential of cannabis has been known for centuries. Cannabinoids express their effects through two types of receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). Present studies indicate that cannabis-based drugs can make a positive impact in the treatment of different diseases. For many years, multiple sclerosis patients have self-medicated with illegal street cannabis to alleviate spasticity, a common and debilitating symptom that impairs quality of life. Nabiximols is the cannabis-based medicine approved in many countries as an add-on therapy for symptom improvement in patients with spasticity who have not responded adequately to other medications. Adverse events such as dizziness, diarrhoea, fatigue, nausea, headache and somnolence occur quite frequently with nabiximols, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual uptitration. The prerequisite for the therapeutic use of cannabis in Serbia arerequires legal clarification for the use of the drug in a clinical environment

scholarly journals Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients

2014 ◽  
Vol 179 (1) ◽  
pp. 119-127 ◽  
Author(s):  
A. J. Sánchez López ◽  
L. Román-Vega ◽  
E. Ramil Tojeiro ◽  
A. Giuffrida ◽  
A. García-Merino
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Longitudinal Study ◽  
Lymphocyte Subsets ◽  
Cannabinoid Receptor ◽  
Receptor Gene ◽  
Interferon Β ◽  
Multiple Sclerosis Patients ◽  
Receptor Gene Expression

Therapeutic potential of human mesenchymal cells from Multiple Sclerosis patients in EAE

2014 ◽  
Vol 275 (1-2) ◽  
pp. 190
Author(s):  
Coral González García ◽  
Laura Román Vega ◽  
Lucía Campos Ruíz ◽  
Elvira Ramil Tojeiro ◽  
Mercedes Zurita Castillo ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Therapeutic Potential ◽  
Mesenchymal Cells ◽  
Multiple Sclerosis Patients

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist

2004 ◽  
Vol 10 (3) ◽  
pp. 330-332 ◽  
Author(s):  
B W van Oosten ◽  
J Killestein ◽  
E MH Mathus-Vliegen ◽  
C H Polman
Keyword(s):  
Multiple Sclerosis ◽  
Animal Models ◽  
Receptor Antagonist ◽  
Human Disease ◽  
Cannabinoid Receptor ◽  
Therapeutic Potential ◽  
Laboratory Research ◽  
Cannabinoid Receptor 1 ◽  
Disease Pathogenesis

Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabino id recepto r antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabino id system might indeed be relevant to disease pathogenesis in MS.

scholarly journals Urinary Catheterization May Not Adversely Impact Quality of Life in Multiple Sclerosis Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Rebecca James ◽  
Heidi E. Frasure ◽  
Sangeeta T. Mahajan
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Negative Impact ◽  
Positive Impact ◽  
Foley Catheter ◽  
Urinary Catheterization ◽  
Urine Leakage ◽  
Multiple Sclerosis Patients ◽  
The Impact

Background. Multiple sclerosis (MS) healthcare providers (HCP) have undergone considerable educational efforts regarding the importance of evaluating and treating pelvic floor disorders, specifically, urinary dysfunction. However, limited data are available to determine the impact of catheterization on patient quality of life (QoL). Objectives. To describe the use of urinary catheterization among MS patients and determine the differences between those who report positive versus negative impact of this treatment on QoL. Methods. Patients were queried as part of the 2010 North American Research Committee On Multiple Sclerosis survey; topics included 1) urinary/bladder, bowel, or sexual problems; 2) current urine leakage; 3) current catheter use; 4) catheterizing and QoL. Results. Respondents with current urine leakage were 5143 (54.7%), of which 1201 reported current catheter use (12.8%). The types of catheters (intermittent self-catheterization and Foley catheter (indwelling and suprapubic)) did not differ significantly. Of the current catheter users, 304 (25.35%) respondents reported catheterization negatively impacting QoL, 629 (52.4%) reported a positive impact on QoL, and 223 (18.6%) reported neutral QoL. Conclusions. A large proportion of catheterized MS patients report negative or positive changes in QoL associated with urinary catheterization. Urinary catheterization does not appear to have a universally negative impact on patient QoL.

scholarly journals The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Wessam Mustafa ◽  
Nadia Elgendy ◽  
Samer Salama ◽  
Mohamed Jawad ◽  
Khaled Eltoukhy
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Symptoms ◽  
Positive Impact ◽  
Control Groups ◽  
Serum Cytokines ◽  
Tnf Α ◽  
Significant Difference ◽  
Bladder Symptoms ◽  
Multiple Sclerosis Patients ◽  
And Control

Background. Multiple studies have reported that cannabis administration in multiple sclerosis patients is associated with decreased symptom severity. This study was conducted to evaluate the prevalence of cannabis abuse in multiple sclerosis cases and to evaluate the effect of cannabis on serum cytokines in such cases. Patients and Methods. A total of 150 multiple sclerosis cases along with 150 healthy controls were included during the study period. All cases were subjected to history taking, neurological examination, and routine investigations. Cases were asked about cannabis intake which was confirmed by a urine test. Serum cytokines including IL-1, IL-2, IL-4, IL-10, IL-12, IL-17, IL-22, IFN-γ, IFN-β1, and TNF-α were ordered for all cases and controls. Results. Twenty-eight cases were cannabis abusers (MS/cannabis group, 18.67%). The remaining 122 cases represented the MS group. There was no significant difference between the three groups regarding age, disease duration, or MS type. Male gender was more predominant in the MS/cannabis group, and the number of relapses was significantly lower in the same group. Fifteen cases (53.6%) reported that their symptoms were improved by cannabis. Proinflammatory cytokines were significantly elevated in the MS group compared to the MS/cannabis and control groups. Additionally, anti-inflammatory cytokines had significantly lower values in the MS group compared to the MS/cannabis and control groups. Most clinical symptoms were significantly improved in the MS/cannabis group compared to the MS group apart from sexual dysfunction, bladder symptoms, and visual disturbances. Mild side effects of cannabis were also reported. Conclusion. Cannabis may have a positive impact on the cytokine and clinical profiles in cases with multiple sclerosis.

scholarly journals Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry

2021 ◽  
Author(s):  
María S. García-Gutiérrez ◽  
Francisco Navarrete ◽  
Ani Gasparyan ◽  
Jorge Manzanares
Keyword(s):  
Cannabinoid Receptor ◽  
Therapeutic Potential ◽  
Relevant Literature ◽  
Brain Regions ◽  
Cannabinoid Receptor 2 ◽  
Pathological Conditions ◽  
Anxiety Depression ◽  
Neuropsychiatric Conditions

Since the identification and cloning of the cannabinoid receptor 2 (CB2R), several studies focused on the characterization of its physiological and pathological role. Initially, CB2R was considered as the peripheral cannabinoid receptor due to its detection in the rat spleen and leukocyte subpopulation in humans. Later, CB2R was identified in different brain regions significantly modifying the landscape and pointing out its role in a wide variety of central physiological functions and pathological conditions. Additional research also detected the expression of CB2R in neurons, microglia, and astroglia in different brain regions. Indeed, the findings collected to date support a significant function of CB2R in anxiety, depression, schizophrenia, and additional neuropsychiatric disorders. This review gathers the most relevant literature regarding new advances about the role of CB2R in a variety of neuropsychiatric conditions, with special emphasis on its potential as a new therapeutic target for the treatment of different psychiatric disorders.

Sign in / Sign up

Export Citation Format

Share Document